Abstract

The role of Interleukin(IL)-6 in the pathogenesis of joint and systemic inflammation in rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis (s-JIA) has been clearly demonstrated. However, the mechanisms by which IL-6 contributes to the pathogenesis are not completely understood. This study investigates whether IL-6 affects, alone or upon toll like receptor (TLR) ligand stimulation, the production of inflammatory cytokines and chemokines in human peripheral blood mononuclear cells (PBMCs), synovial fluid mononuclear cells from JIA patients (SFMCs) and fibroblast-like synoviocytes from rheumatoid arthritis patients (RA synoviocytes) and signalling pathways involved. PBMCs were pre-treated with IL-6 and soluble IL-6 Receptor (sIL-6R). SFMCs and RA synoviocytes were pre-treated with IL-6/sIL-6R or sIL-6R, alone or in combination with Tocilizumab (TCZ). Cells were stimulated with LPS, S100A8-9, poly(I-C), CpG, Pam2CSK4, MDP, IL-1β. Treatment of PBMCs with IL-6 induced production of TNF-α, CXCL8, and CCL2, but not IL-1β. Addition of IL-6 to the same cells after stimulation with poly(I-C), CpG, Pam2CSK4, and MDP induced a significant increase in IL-1β and CXCL8, but not TNF-α production compared with TLR ligands alone. This enhanced production of IL-1β and CXCL8 paralleled increased p65 NF-κB activation. In contrast, addition of IL-6 to PBMCs stimulated with LPS or S100A8-9 (TLR-4 ligands) led to reduction of IL-1β, TNF-α and CXCL8 with reduced p65 NF-κB activation. IL-6/IL-1β co-stimulation increased CXCL8, CCL2 and IL-6 production. Addition of IL-6 to SFMCs stimulated with LPS or S100A8 increased CXCL8, CCL2 and IL-1β production. Treatment of RA synoviocytes with sIL-6R increased IL-6, CXCL8 and CCL2 production, with increased STAT3 and p65 NF-κB phosphorylation. Our results suggest that IL-6 amplifies TLR-induced inflammatory response. This effect may be relevant in the presence of high IL-6 and sIL-6R levels, such as in arthritic joints in the context of stimulation by endogenous TLR ligands.

Highlights

  • Interleukin-6 (IL-6) is a pleiotropic cytokine with multiple functions in different pathophysiologic systems [1,2]

  • We focused on p65 NF-kB, where signals elicited by toll like receptor (TLR) and IL-6 may converge, as previously suggested by us and others [9,14]. p65 NF-kB plays a major role in inflammatory cytokine and chemokine production upon TLR ligand stimulation and is involved in arthritis pathogenesis [9,18]

  • Serine536-NF-kB phosphorylation was increased in the presence of soluble IL-6 Receptor (sIL-6R) alone and was markedly reduced by TCZ both in untreated cells and in cells stimulated with IL-1b and LPS. These results demonstrate that high levels of IL-6/sIL-6R, as those present in joints of patients with arthritis, may contribute to the amplification of the inflammatory response enhancing the production of IL-1b, CXCL8 and CCL2 by synovial fluid mononuclear cells from JIA patients (SFMCs) and by rheumatoid arthritis (RA) synoviocytes

Read more

Summary

Introduction

Interleukin-6 (IL-6) is a pleiotropic cytokine with multiple functions in different pathophysiologic systems [1,2]. The recent introduction of tocilizumab (TCZ), an IL-6 receptor blocker, in the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis (s-JIA), clearly demonstrated a major role of this cytokine in the pathogenesis of joint and systemic inflammation [4,5]. IL-6 has a role in the differentiation of B lymphocyte into auto-antibody producing plasma cells, which participate in the pathogenesis of arthritis through the formation of immune complexes (IC) [6]. High levels of IL-6 may cause a Th17/Treg cell imbalance during RA, which is corrected upon treatment with TCZ [7,8]. IL-6 mediated B and T lymphocyte dysregulation may lead to abnormal production of inflammatory cytokines, chemokines and metalloproteases by both leukocytes and cells of the synovial stroma, leading to synovial tissue degradation and bone erosions

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call